Published on: 08 December 2015
A must-watch: Dr Manisha A. Desai, assistant general patent counsel at Eli Lilly and Company, gives her take on the importance of the Convention of Biodiversity and the Nagoya Protocol for the pharma industry. What’s key is to increase the awareness of the potential impacts of the Nagoya Protocol on research and on our ability to respond to a public health emergency.
